✦ LIBER ✦

PCN10 COSTS OF MANAGING TOXICITIES IN ADVANCED NON-SMALL CELL LUNG CANCER WITH PEMETREXED COMPARED WITH DOCETAXEL AS SECOND-LINE CHEMOTHERAPY

✍ Scribed by M Aristides; D Jackson; AM Liepa; NB Leighl; F Shepherd

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN120 COST-UTILITY OF DOCETAXEL COMPARE

✍ J Rutkowski; B Gwiosda; B Lisiecka; M Wladysiuk; J Lis; R Plisko; P Rys 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Clinical study of docetaxel-vinorelbine

✍ Jun Guo; Weiping Li; Degang Song; Zhehai Wang; Jie Liu; Changzheng Li; Zhen Chen 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 77 KB

Phase I study of second-line chemotherap

✍ Mikio Oka; Minoru Fukuda; Seiji Nagashima; Masaaki Fukuda; Akitoshi Kinoshita; H 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 84 KB

A retrospective study of pemetrexed comb

✍ Xin-xing Zhang; Mei-juan Huang; You-ling Gong; Lin Zhou; Yong-mei Liu; Jiang Zhu 📂 Article 📅 2011 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 185 KB